Digoxin and Paricalcitol interaction
Digoxin and Paricalcitol: the Paricalcitol prescribing label describes an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Paricalcitol label · effective 2024-07-30
Digitalis Toxicity: Risk increases with hypercalcemia.
In patients using digitalis compounds, monitor both serum calcium and patients for signs and symptoms of digitalis toxicity.
Acute hypercalcemia may increase the risk of cardiac arrhythmias and seizures and may potentiate the effect of digitalis on the heart [see Warnings and Precautions (5.2) ] .
Digitalis Toxicity Paricalcitol Injection can cause hypercalcemia [see Warnings and Precautions (5.1) ] which increases the risk of digitalis toxicity.
In patients using Paricalcitol Injection concomitantly with digitalis compounds, monitor serum calcium and patients for signs and symptoms of digitalis toxicity.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.